Pragati Aniket Manoli

Pragati Aniket Manoli

Auto-generated profile, based on publicly available information

Pragati Aniket Manoli

Department of Microbiology, KLE Jagadguru Gangadhar Mahaswamigalu Moorusaavirmath Medical College, Huballi KLE Academy of Higher Education and Research, Karnataka, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in Health Leadership and Quality of Life
Verified
Journal Article
Open access
PDF file
PMPragati Aniket Manoli
Pragati Aniket Manoli
RGRashmi Gudur
Rashmi Gudur
JKJatin Khurana
Jatin Khurana
ASAakash Sharma
Aakash Sharma
PRPramod Reddy
Pramod Reddy
SPSoumya Surath Panda
Soumya Surath Panda
Cancer is still one of the main reasons of death in the world, and treating cancers in their later stages is very hard. Chemotherapy and immunotherapy are the two main ways to treat advanced cancer. They work in different ways and have different benefits and drawbacks. This essay looks at chemotherapy and immunotherapy side by side, comparing how well they work, how safe they are, and how they affect patient results when treating advanced cancers. Chemotherapy is a common treatment that targets cancer cells that divide quickly. This shrinks the growth and stops the disease from getting worse. While chemotherapy has been shown to help some types of cancer, it often comes with serious side effects like weakened immune systems, stomach problems, and hair loss that can make patients' quality of life very bad. Immunotherapy, on the other hand, uses the immune system to find cancer cells and kill them. Immunotherapy, on the other hand, can cause long-lasting recovery by activating immune reactions that target cancer cells, and in some cases, it has fewer side effects. Several methods are used in this method, including immune checkpoint inhibitors, monoclonal antibodies, and cancer medicines. Immunotherapy has shown promise in treating cancers that didn't respond to treatment before, like melanoma, lung cancer, and some types of lymphoma. On the other hand, immunotherapy can cause immune-related side effects like swelling in good organs, which could lead to major problems. This review looks at the most important studies and clinical trials that have compared how well and safely chemotherapy and immunotherapy treat advanced cancer. We look at the rates of reaction, total survival, progression-free survival, and unfavorable events that happen with these different types of treatment. The study also talks about the things that affect the choice of treatment, such as the type of cancer, the patient's health, and their previous treatment history.

4 August 2025 in Health Leadership and Quality of Life
Verified
Journal Article
Open access
PDF file
PMPragati Aniket Manoli
Pragati Aniket Manoli
SRSourav Rampal
Sourav Rampal
BBBathala Balaji
Bathala Balaji
SSSudam Sadangi
Sudam Sadangi
MSMinerva Singh
Minerva Singh
VMVibhor Mahajan
Vibhor Mahajan
The tumor microenvironment (TME) is very important for how cancer starts, grows, and becomes resistant to treatment. It is made up of different kinds of cells, like cancer cells, immune cells, fibroblasts, vascular cells, and extracellular matrix (ECM) components. These cells interact with each other to make a complicated and changing environment that affects how the tumor behaves. Understanding the TME is important for making cancer treatments better because it helps us understand how immune systems hide cancer, how it spreads, and how drugs don't work on it. This abstract looks at ways to improve cancer treatment by learning more about the TME. One potential method is to target immune cells in the TME, like tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells, which often help the immune system tolerate the tumor and it grows. It is possible to recover immune function and make immunotherapies like immune checkpoint inhibitors work better by changing these groups of immune cells. Disrupting the ECM is another approach. The ECM not only supports the shape of the tumor but also controls cell communication and the growth of drug tolerance. To improve drug transport and stop tumor spread, scientists are looking into agents that target ECM components or enzymes that change it. The TME's blood vessels are another important part of how the growth grows. Problematic blood veins can make it harder for healing agents to get to where they need to go, which makes drugs less effective. Strategies like arterial normalization or using nanomedicine to target blood vessels that leak have shown promise in making it easier for drugs to get into cells and treatment to work better. Targeting the metabolic reprogramming of tumor cells and the TME's changed food supply can also make treatments more effective, especially when they are used with radiation or chemotherapy.